Mermel is Professor of Medicine at the Warren Alpert Medical School of Brown University. Mermel joins Isaam Raad, the chair of MD Anderson Cancer Center's Department of Infectious Diseases (also chairman of the Citius Scientific advisory board), and Mark Rupp, Professor and Chief of the Division of Infectious Diseases at the University of Nebraska Medical Center.
The advisory board will be counseling the company on its development programs, particularly the anti-infective portfolio which includes the company's lead technology, Mino-Lok.
Citius' Mino-Lok product is designed to salvage infected central venous catheters (CVCs) that cause catheter related bloodstream infections (CRBSIs). This is a recognized unmet medical need, as there have been no large scale studies to provide robust evidence on the effectiveness of antibiotic lock therapies.
The company's Mino-Lok product contains a proprietary combination of minocycline, edetate (disodium EDTA), and ethyl alcohol, all of which act synergistically to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter.
Citius is dedicated to the development and commercialization of critical care products, with a focus on anti-infectives, cancer care, and unique prescription products that use innovative, patented or proprietary formulations of previously-approved active pharmaceutical ingredients.
EDX Medical and Spire Healthcare sign strategic diagnostic partnership agreement
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
Ondine's Steriwave proven effective against deadly Mucor fungus
Mycovia Pharmaceuticals reports first participant enrolled in Phase 2 cryptococcal meningitis study
bioMérieux launches rapid PCR test for equine respiratory diseases
Ondine Biomedical joins CAN Health Network to advance Steriwave adoption in Canada
Seegene presrnts CURECA conceptual video at ESCMID Global 2025
GC Biopharma's BARYTHRAX receives Korean regulatory approval
bioMérieux receives CE-marking for LUMED APSS to support antimicrobial stewardship in Europe
Ondine Biomedical's Steriwave technology reduces surgical site infections by 71% in NHS deployment
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Ireland selects Conduent to enhance infectious disease management